Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
Abstract Background Immunocheckpoint inhibitor(ICI) is a major breakthrough in tumor treatment. It can activate the patient’s own immune system and play an anti-tumor role, but not all patients can benefit from it. At present, there is still a lack of effective biomarkers to guide clinical applicati...
Main Authors: | Fei Zheng, Qingju Meng, Lei Zhang, Jingli Chen, Liyan Zhao, Zhiguo Zhou, Yibing Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12957-023-03077-8 |
Similar Items
-
Checkpoint inhibition in hematologic malignancies
by: Aaron Tsumura, et al.
Published: (2023-10-01) -
Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021-08-01) -
Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
by: WANG Yijie, et al.
Published: (2022-11-01) -
Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01) -
Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors
by: Hebin Che, et al.
Published: (2022-08-01)